Journal: Advanced Science
Article Title: Targeting a Calcium‐Associated Mitochondrial Vulnerability in TET2‐Deficient Myeloid Cells
doi: 10.1002/advs.78748
Figure Lengend Snippet: Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Article Snippet: To identify compounds that preferentially compromise TET2 ‐KD macrophages, we performed chemical‐genetic screening using 489 cardiovascular disease‐related bioactive compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library (Figure and Extended Data Table ).
Techniques: Screening, Derivative Assay, Drug discovery, Preserving, Biomarker Discovery, Alamar Blue Assay, Activity Assay, MTS Assay, Transfection, Enzyme-linked Immunosorbent Assay, RNA Sequencing